Tier 2 — strong

Impact of the Natural Compound Urolithin A on Health, Disease, and Aging

D'Amico D, Andreux PA, Valdés P, Singh A, Rinsch C, Auwerx J
Trends in Molecular Medicine 2021 27(7):687-699

Bibliography

PubMed
PMID 34030963
DOI
10.1016/j.molmed.2021.04.009
Funding
Not disclosed as a separate statement in the sections of the article reviewed for this entry. The study product was supplied by Amazentis SA, whose employees make up the majority of the author list — see the competing-interests note for the relevant disclosure this implies.
Competing interests
Four of six authors are Amazentis SA employees (the manufacturer of Urolithin A/Mitopure); a fifth (Johan Auwerx, EPFL) is a long-standing academic collaborator on Amazentis-affiliated urolithin A research. A formal conflict-of-interest statement was not captured in the sections of the article reviewed for this entry, but this affiliation pattern is the relevant disclosure — this review should be read as an industry-linked synthesis rather than an independent academic review.

Study snapshot

DesignNarrative review
ModelNot applicable — literature review spanning preclinical and human urolithin A studies
SampleNot applicable
InterventionNot applicable — reviews urolithin A's mechanisms (mitophagy, mitochondrial function, inflammation) and evidence across muscle, brain, joint, and other organ systems
DurationNot applicable
EndpointsNarrative synthesis of urolithin A mechanism and evidence across preclinical models and early human trials

What the study showed, in plain terms

This 2021 review, written mainly by researchers affiliated with Amazentis SA (the company that manufactures and markets Urolithin A as Mitopure), summarises the case for urolithin A as a longevity-relevant compound: a gut-bacteria metabolite of foods like pomegranate and berries that activates mitophagy — the clearance of damaged mitochondria — and appears to improve muscle, joint, and other tissue health in animal models, with early human trial support specifically in muscle.

As a summary of the field, it is useful for orientation. As an independent verdict on urolithin A's evidence base, it should be read cautiously — the majority of its authors work for, or have close research ties to, the company that sells the ingredient it reviews favourably.

Key findings

  • Urolithin A activates mitophagy and reduces inflammation across preclinical models: the review summarises protective effects in animal models of muscle, brain, joint (osteoarthritis), cardiac, and inflammatory bowel conditions.
  • Human evidence is concentrated in muscle health: the review highlights the same clinical trials — the first-in-human safety trial and the muscle-strength ATLAS trial — that are separately catalogued in this Data Center, rather than presenting independent new human data.

What this study can and cannot tell us

Heavily industry-affiliated authorship. Four of six authors are Amazentis SA employees, and the review's favourable framing should be read in that light rather than treated as an independent academic assessment.

Narrative, not systematic. No pre-registered systematic search or screening methodology is described.

Does not add new primary evidence. The human clinical evidence cited is the same small set of company-run trials already catalogued individually in this Data Center.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability